Phase II study of vinflunine in patients with metastatic renal cell carcinoma

Investigational New Drugs
D GoldsteinM Byrne

Abstract

An open-label, multicentre, non-comparative phase II trial to determine the response rate of intravenous vinflunine as first line chemotherapy in patients with metastatic renal cell carcinoma (RCC). Patients with metastatic RCC were treated with vinflunine 350 mg/m2 (n = 11) or 320 mg/m2 (n = 22) administered intravenously every 21 days. Out of 33 patients included in this study, one partial response was observed in the group treated at 350 mg/m2 and none in the group receiving 320 mg/m2 resulting in a response rate in this population of 9.1% (95% CI: 0.2-41.3). Median progression free survival was 5.6 months (95% CI: 2.8-14.4) for patients treated at 350 mg/m2, and 3.3 months (95% CI: 1.6-6.4) for those treated at 320 mg/m2.The median survival time was 10.4 months (95% CI: 6.8-12.4) for the whole study population. The principal toxicities were grade 3/4 neutropaenia -90.9% at 350 mg/m2 and 68.1% at 320 mg/m2, febrile neutropaenia was recorded in 3 patients (27.3%) at 350 mg/m2 and in 5 patients (22.7%) at 320 mg/m2. One episode of thromboembolic event was reported in 1 patient at each dose level. Vinflunine given intravenously once every 3 weeks has not shown any clinically relevant activity in the management of patients with ...Continue Reading

References

Nov 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B L WeberJ Hohneker
Aug 17, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B T HillA Kruczynski
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S PyrhönenP L Kellokumpu-Lehtinen
Jan 27, 2000·The Journal of Urology·R J Motzer, P Russo
Apr 28, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerE M Metz
Jun 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B I RiniW M Stadler
Mar 22, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J BennounaM Marty
Aug 2, 2003·The New England Journal of Medicine·James C YangSteven A Rosenberg

❮ Previous
Next ❯

Citations

Oct 17, 2006·Expert Opinion on Investigational Drugs·Mark R Miglarese, Robert O Carlson
Mar 28, 2008·Expert Opinion on Investigational Drugs·Adrian Yun-San YipLouis Wing-Cheong Chow
May 2, 2008·Expert Opinion on Investigational Drugs·Robert O Carlson
Apr 29, 2011·Expert Opinion on Drug Safety·Fabio A B SchutzToni K Choueiri
Jul 20, 2010·Annales pharmaceutiques françaises·C Monneret
Jul 17, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·I N OlverM C Pinel
Jun 30, 2010·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·John S Ng
Feb 20, 2007·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·James A InciardiTheodore J Cicero
Feb 6, 2009·Expert Review of Anticancer Therapy·Patrick G Morris, Monica N Fornier
Oct 27, 2011·Anti-cancer Drugs·Luis Miguel Anton AparicioGuadalupe Aparicio Gallego
Dec 15, 2010·The Oncologist·Lee D CranmerSherif S Morgan
Apr 5, 2013·Anti-cancer Drugs·Sebastiano ButiFrancesco Massari

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
I N OlverM C Pinel
Expert Opinion on Investigational Drugs
Jaafar BennounaMarie-Claire Pinel
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Cristina SuárezJoan Carles
© 2021 Meta ULC. All rights reserved